Acotec Scientific Holdings Limited (HKG:6669)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
14.84
+0.21 (1.44%)
Feb 11, 2026, 3:25 PM HKT
Market Cap4.58B +162.7%
Revenue (ttm)649.64M +13.3%
Net Income110.56M +214.6%
EPS0.36 +210.2%
Shares Out313.39M
PE Ratio40.42
Forward PE35.92
Dividendn/a
Ex-Dividend Daten/a
Volume234,378
Average Volume327,938
Open14.77
Previous Close14.63
Day's Range14.59 - 14.99
52-Week Range5.56 - 15.47
Beta0.21
RSI60.27
Earnings DateMar 25, 2026

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ... [Read more]

Sector Healthcare
Founded 2011
Employees 645
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6669
Full Company Profile

Financial Performance

In 2024, HKG:6669's revenue was 533.99 million, an increase of 12.69% compared to the previous year's 473.85 million. Earnings were 52.28 million, an increase of 260.88%.

Financial numbers in CNY Financial Statements